Application of berberrubine in preparation of medicine for treating asthma
By targeting Ezrin protein with berberine, airway smooth muscle is relaxed, which solves the problem of insufficient regulation of airway smooth muscle cell function in existing asthma treatments, and achieves effective relief of asthma symptoms and improvement of ventilation function.
Patent Information
- Application Number
- CN202610161021.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-02-04
- Publication Date
- 2026-06-02
AI Technical Summary
Existing asthma treatments have failed to adequately target the functional regulation of airway smooth muscle cells, particularly with insufficient intervention in their cytoskeleton remodeling and contractile protein activation. This results in some patients having poor symptom control, a high risk of acute exacerbations, and limited efficacy in treating refractory asthma.
Berberrubine chloride is used to target actin-binding protein Ezrin, relax airway smooth muscle, relieve airway resistance in asthma patients, and improve ventilation function.
Berberine can effectively target Ezrin, inhibit the contraction of airway smooth muscle cells, significantly relax airway smooth muscle, and improve asthma symptoms, showing broad application prospects.